WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it will take center stage at two major healthcare investor conferences in February, giving Wall Street and industry watchers a fresh look at the company’s strategy and pipeline as interest builds around immuno-inflammatory drug development.
The clinical-stage biopharmaceutical company announced that its leadership team will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference later this month.
On Thursday, February 12, 2026, at 2:30 p.m. EST, Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City. The event brings together executives and investors focused on emerging trends and companies shaping the biotechnology sector.
Later in the month, on Thursday, February 26, 2026, at 8:40 a.m. EST, President and Chief Operating Officer Hugh Davis, Ph.D., will deliver a corporate presentation during the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference, one of the industry’s longest-running investor forums.
A live and archived webcast of both events will be available on the Events page of the company’s website at https://www.aclaristx.com/. The replays are expected to remain accessible for at least 30 days following each presentation.
Aclaris Therapeutics is focused on developing a pipeline of novel therapies aimed at patients with immuno-inflammatory diseases who lack adequate treatment options. The company said its multi-stage portfolio is supported by an internal research and development engine designed to advance new product candidates from discovery through clinical development.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.